Website Information
    Web Site Information :.   Site Info    Whois    Traceroute    RBL Check  

Enter Web Site URL Address:
 

novartispharma.at: Novartis Pharma - Novartis Austria
Alles übr den Geschäftsbereich Novartis Pharma Austria  
 
 

Novartis Pharma - Novartis Austria

Description: Alles übr den Geschäftsbereich Novartis Pharma Austria

Keywords: Geschäftsbereich, Novartis, Pharma, Wien, vertrieb, verschreibungspflichtig, Arzneimittel, Forschung, Therapie

Tags: novartispharma, novartis, pharma, austria, bei, den, willkommen, für, geschäftsbereich, geschäftsbereiche, informationen, large, reg, skip, text, size, health, home, wien, übr, alles, über, und, forschung, arzneimittel, vertrieb, consumer, animal, produkte, therapie, verschreibungspflichtig, patienten, kontakt, fachkreise, lieferanten, increase, seite, empfehlen, decrease, print,

Novartispharma.at

Content Revalency: Title: 100.00%   Description: 57.14%   Keywords: 66.67%  |  Document size: 29,697 bytes
More info: Whois - Trace Route - RBL Check
 
NOVARTISPHARMA.AT - Site Location
Country/Flag US United States
City/Region/Zip Code , ,
Organization Verizon Business
Internet Service Provider Verizon Business
 
NOVARTISPHARMA.AT - Domain Information
Domain novartispharma.at   [ Traceroute  RBL/DNSBL lookup ]
Whois server whois.nic.at
Created --
Updated --
Expires --
Time Left 0 days 0 hours 0 minutes
DNS servers dns1.novartis.com   160.62.1.75
dns2.novartis.com   160.62.1.76
mia03-1.digex.com   164.109.2.40
 
NOVARTISPHARMA.AT - DNS Information
IP Address 164.109.93.60 ~ Whois - Trace Route - RBL Check
Domain Name Servers dns2.novartis.com   160.62.7.59
mia03-1.digex.com  
dns1.novartis.com   160.62.4.7
Mail Exchange mail.nextra.at  
fallback.nextra.at  
 
Site Response Header
Response HTTP/1.1 302 Found
Server WS
Date Thu, 14 Apr 2011 23:23:35 GMT
Content-Type text/html;charset=UTF-8
Cookie JSESSIONID=XX9LNnBXvK7b2xHrG9vrW1GnZ4hbDJRrmnJTtXZHpNF7WSBPhrx9!-528929384; path=/


  IP Index    TLD Index    Domain Index    Site Index New   Copyright © 2025 Cybernet Quest.